diaDexus licenses prostate test to SmithKline Beecham
This article was originally published in Clinica
SmithKline Beecham's clinical laboratories division (SBCL) has obtained the exclusive rights from diaDexus to use and further improve a blood test that measures stages of development of prostate cancer. The test, called PLA2, is the first product developed and licensed by diaDexus, a Santa Clara, California-based joint venture formed in 1997 by SmithKline Beecham and Incyte Pharmaceuticals (Clinica No 773, p 9).
You may also be interested in...
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.
At the OurCrowd Global Investor Summit, in Jerusalem, Israel, on 13 February, Medtech Insight met with start-up Sweetch, which has developed a personalized digital health coach for wellness and disease management.
Medtech Insight attended the OurCrowd Global Investor Summit in Jerusalem on February 13. At the meeting, Ofer Barnea, CEO of neurosurgery start-up SynCath Neuroscience, explained his company’s device to treat cerebral edema,